Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.’s FY2018 Earnings (ORMP)

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) – Equities research analysts at B. Riley lifted their FY2018 earnings per share (EPS) estimates for shares of Oramed Pharmaceuticals in a research note issued to investors on Tuesday. B. Riley analyst A. D’silva now expects that the biotechnology company will earn ($1.10) per share for the year, up from their previous forecast of ($1.13). B. Riley currently has a “Buy” rating and a $20.00 target price on the stock.

A number of other equities research analysts have also recently commented on ORMP. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a research note on Thursday, October 5th. ValuEngine cut Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th.

Oramed Pharmaceuticals (NASDAQ:ORMP) traded up $0.08 during trading on Thursday, reaching $8.42. The company’s stock had a trading volume of 20,200 shares, compared to its average volume of 28,118. Oramed Pharmaceuticals has a 52 week low of $5.85 and a 52 week high of $11.34. The stock has a market capitalization of $119.76, a PE ratio of -10.94 and a beta of 1.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Wednesday, November 29th. The biotechnology company reported ($0.20) EPS for the quarter. Oramed Pharmaceuticals had a negative net margin of 169.17% and a negative return on equity of 49.94%.

Large investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in shares of Oramed Pharmaceuticals by 4.4% in the second quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 625 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of Oramed Pharmaceuticals in the second quarter worth about $125,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Oramed Pharmaceuticals in the third quarter worth about $185,000. Hedge funds and other institutional investors own 1.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.’s FY2018 Earnings (ORMP)” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://stocknewstimes.com/2018/01/18/analysts-issue-forecasts-for-oramed-pharmaceuticals-inc-s-fy2018-earnings-ormp.html.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply